Ultragenyx Pharmaceutical Ownership 2024 | Who Owns Ultragenyx Pharmaceutical Now?
Institutional Ownership
12.76%
Insider Ownership
3.66%
Retail Ownership
83.58%
Institutional Holders
103.00
Ultragenyx Pharmaceutical Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | 11.60% | 0.01% | 9,780,493 | 1,080,486 | 12.42% | 401,978,262 | Jun 30, 2024 |
| BLACKROCK INC. | 6.65% | 0.01% | 5,603,352 | 367,614 | 7.02% | 230,297,768 | Jun 30, 2024 |
| SANDS CAPITAL MANAGEMENT, LLC | 6.35% | 0.65% | 5,354,750 | 1,495,303 | 38.74% | 220,080,225 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.41% | 0.03% | 4,556,167 | 458,192 | 11.18% | 187,258,464 | Jun 30, 2024 |
| RTW INVESTMENTS, LP | 3.87% | 2.07% | 3,259,927 | -3,827,188 | -54.00% | 133,983,000 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.55% | 0.01% | 2,991,958 | -576,915 | -16.17% | 122,970,000 | Jun 30, 2024 |
| STATE STREET CORP | 3.20% | 0.00% | 2,697,101 | -154,149 | -5.41% | 110,850,851,000 | Jun 30, 2024 |
| CLEARBRIDGE INVESTMENTS, LLC | 2.79% | 0.08% | 2,353,804 | -47,050 | -1.96% | 96,741,330 | Jun 30, 2024 |
| ALKEON CAPITAL MANAGEMENT LLC | 2.66% | 0.15% | 2,241,832 | - | - | 92,139,295 | Jun 30, 2024 |
| FEDERATED HERMES, INC. | 2.50% | 0.21% | 2,107,025 | 168,345 | 8.68% | 86,598,728,000 | Jun 30, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.45% | 3.11% | 2,061,426 | 384,615 | 22.94% | 84,724,609 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 2.28% | 2.38% | 1,924,072 | 149,134 | 8.40% | 79,079,359 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.20% | 0.04% | 1,850,734 | 1,142,829 | 161.44% | 76,065,167 | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | 2.14% | 5.52% | 1,800,000 | 1,690,000 | 1536.36% | 73,980,000 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 2.11% | 0.03% | 1,782,340 | 575,115 | 47.64% | 73,254,174 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 1.81% | 0.02% | 1,527,875 | 45,404 | 3.06% | 62,795,663 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.79% | 0.01% | 1,505,458 | 165,632 | 12.36% | 61,891,491 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 1.74% | 0.77% | 1,466,547 | - | - | 60,275,082 | Jun 30, 2024 |
| INVESCO LTD. | 1.50% | 0.01% | 1,268,318 | 765,466 | 152.22% | 52,127,869 | Jun 30, 2024 |
| MARSHALL WACE, LLP | 1.34% | 0.06% | 1,133,100 | 164,110 | 16.94% | 46,570,410 | Jun 30, 2024 |
Ultragenyx Pharmaceutical's largest institutional shareholder is VANGUARD GROUP INC, holding 11.60% of the company's total share outstanding, currently valued at $401.98M. The top 10 institutional shareholders own together 48.58% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VESTAL POINT CAPITAL, LP | 2.14% | 5.52% | 1,800,000 | 1,690,000 | 1536.36% | 73,980,000 | Jun 30, 2024 |
| CUTTER CAPITAL MANAGEMENT, LP | 0.43% | 4.53% | 365,000 | 365,000 | 100.00% | 15,001,500 | Jun 30, 2024 |
| EAGLE HEALTH INVESTMENTS LP | 0.62% | 3.78% | 524,500 | 224,800 | 75.01% | 21,556,950 | Jun 30, 2024 |
| FIRST LIGHT ASSET MANAGEMENT, LLC | 1.14% | 3.47% | 963,146 | 172,700 | 21.85% | 39,585,301 | Jun 30, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.45% | 3.11% | 2,061,426 | 384,615 | 22.94% | 84,724,609 | Jun 30, 2024 |
| BLUE OWL CAPITAL HOLDINGS LP | 0.32% | 3.07% | 268,238 | - | - | 11,024,582 | Jun 30, 2024 |
| PRIVIUM FUND MANAGEMENT B.V. | 0.30% | 2.63% | 251,602 | 36,500 | 16.97% | 10,305,618 | Jun 30, 2024 |
| BIOIMPACT CAPITAL LLC | 0.45% | 2.43% | 380,552 | 134,962 | 54.95% | 15,640,687 | Jun 30, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 2.28% | 2.38% | 1,924,072 | 149,134 | 8.40% | 79,079,359 | Jun 30, 2024 |
| RTW INVESTMENTS, LP | 3.87% | 2.07% | 3,259,927 | -3,827,188 | -54.00% | 133,983,000 | Jun 30, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | 1.14% | 1.68% | 960,000 | 26,500 | 2.84% | 39,456,000 | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.35% | 1.65% | 293,832 | 55,288 | 23.18% | 12,076,495 | Jun 30, 2024 |
| ALTIUM CAPITAL MANAGEMENT LP | 0.08% | 1.17% | 70,000 | 70,000 | 100.00% | 2,877,000 | Jun 30, 2024 |
| EFG ASSET MANAGEMENT (NORTH AMERICA) CORP. | 0.15% | 0.89% | 125,561 | 8,725 | 7.47% | 5,161,185 | Jun 30, 2024 |
| EMERALD MUTUAL FUND ADVISERS TRUST | 0.46% | 0.84% | 390,524 | 5,184 | 1.35% | 16,050,536 | Jun 30, 2024 |
| EMERALD ADVISERS, LLC | 0.58% | 0.84% | 486,682 | -1,456 | -0.30% | 20,002,630 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.50% | 0.82% | 425,000 | 425,000 | 100.00% | 17,467,500 | Jun 30, 2024 |
| BAKER BROS. ADVISORS LP | 1.74% | 0.77% | 1,466,547 | - | - | 60,275,082 | Jun 30, 2024 |
| SANDS CAPITAL MANAGEMENT, LLC | 6.35% | 0.65% | 5,354,750 | 1,495,303 | 38.74% | 220,080,225 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.12% | 0.55% | 100,000 | 100,000 | 100.00% | 4,110,000 | Jun 30, 2024 |
The largest Ultragenyx Pharmaceutical shareholder by % of total assets is VESTAL POINT CAPITAL, LP. The company owns 1.80M shares of Ultragenyx Pharmaceutical (RARE), representing 5.52% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VESTAL POINT CAPITAL, LP | 2.14% | 5.52% | 1,800,000 | 1,690,000 | 1536.36% | 73,980,000 | Jun 30, 2024 |
| SANDS CAPITAL MANAGEMENT, LLC | 6.35% | 0.65% | 5,354,750 | 1,495,303 | 38.74% | 220,080,225 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 2.20% | 0.04% | 1,850,734 | 1,142,829 | 161.44% | 76,065,167 | Jun 30, 2024 |
| VANGUARD GROUP INC | 11.60% | 0.01% | 9,780,493 | 1,080,486 | 12.42% | 401,978,262 | Jun 30, 2024 |
| NORGES BANK | 1.19% | 0.01% | 1,002,463 | 1,002,463 | 100.00% | 41,201,229 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.33% | 0.09% | 1,125,000 | 975,000 | 650.00% | 46,237,500 | Jun 30, 2024 |
| INVESCO LTD. | 1.50% | 0.01% | 1,268,318 | 765,466 | 152.22% | 52,127,869 | Jun 30, 2024 |
| DEUTSCHE BANK AG\ | 2.11% | 0.03% | 1,782,340 | 575,115 | 47.64% | 73,254,174 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.64% | 0.06% | 539,749 | 478,849 | 786.29% | 22,183,696 | Jun 30, 2024 |
| MAN GROUP PLC | 0.75% | 0.07% | 628,726 | 475,085 | 309.22% | 25,840,638 | Jun 30, 2024 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.41% | 0.03% | 4,556,167 | 458,192 | 11.18% | 187,258,464 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.50% | 0.82% | 425,000 | 425,000 | 100.00% | 17,467,500 | Jun 30, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.45% | 3.11% | 2,061,426 | 384,615 | 22.94% | 84,724,609 | Jun 30, 2024 |
| BLACKROCK INC. | 6.65% | 0.01% | 5,603,352 | 367,614 | 7.02% | 230,297,768 | Jun 30, 2024 |
| CUTTER CAPITAL MANAGEMENT, LP | 0.43% | 4.53% | 365,000 | 365,000 | 100.00% | 15,001,500 | Jun 30, 2024 |
| BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 0.99% | 0.09% | 830,375 | 323,280 | 63.75% | 34,128,000 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.85% | 0.19% | 716,947 | 276,149 | 62.65% | 29,466,520 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.75% | 0.00% | 629,514 | 265,392 | 72.89% | 25,873,045 | Jun 30, 2024 |
| EAGLE HEALTH INVESTMENTS LP | 0.62% | 3.78% | 524,500 | 224,800 | 75.01% | 21,556,950 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.24% | 0.01% | 203,442 | 203,442 | 100.00% | 8,361,466 | Jun 30, 2024 |
As of Jun 30 2024, Ultragenyx Pharmaceutical's largest institutional buyer is VESTAL POINT CAPITAL, LP. The company purchased 1.69M stocks of RARE, valued at $73.98M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 3.87% | 2.07% | 3,259,927 | -3,827,188 | -54.00% | 133,983,000 | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.55% | 0.01% | 2,991,958 | -576,915 | -16.17% | 122,970,000 | Jun 30, 2024 |
| PICTET ASSET MANAGEMENT HOLDING SA | 0.66% | 0.03% | 556,818 | -479,556 | -46.27% | 22,885,220 | Jun 30, 2024 |
| EVENTIDE ASSET MANAGEMENT, LLC | - | - | - | -359,000 | -100.00% | - | Jun 30, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.00% | 0.00% | 2,482 | -228,285 | -98.92% | 102,804 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -200,300 | -100.00% | - | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | - | - | - | -167,784 | -100.00% | - | Jun 30, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.24% | 0.00% | 204,223 | -159,144 | -43.80% | 8,393,565 | Jun 30, 2024 |
| STATE STREET CORP | 3.20% | 0.00% | 2,697,101 | -154,149 | -5.41% | 110,850,851,000 | Jun 30, 2024 |
| AQR CAPITAL MANAGEMENT LLC | 0.12% | 0.01% | 97,100 | -154,097 | -61.35% | 3,990,810 | Jun 30, 2024 |
| FMR LLC | 0.77% | 0.00% | 647,618 | -134,414 | -17.19% | 26,617,100 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.32% | 0.10% | 266,790 | -133,334 | -33.32% | 10,965,069 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.93% | 0.01% | 781,943 | -129,713 | -14.23% | 32,137,862 | Jun 30, 2024 |
| NEUBERGER BERMAN GROUP LLC | - | - | - | -104,939 | -100.00% | - | Jun 30, 2024 |
| FIRST TRUST ADVISORS LP | 0.33% | 0.01% | 281,093 | -87,126 | -23.66% | 11,552,930 | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | 0.18% | 0.01% | 149,084 | -71,276 | -32.35% | 6,127,352 | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -68,000 | -100.00% | - | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | 0.02% | 0.01% | 14,364 | -65,505 | -82.02% | 590,360 | Jun 30, 2024 |
| BARCLAYS PLC | 0.07% | 0.00% | 62,913 | -55,860 | -47.03% | 2,586,000 | Jun 30, 2024 |
| RAFFERTY ASSET MANAGEMENT, LLC | 0.15% | 0.02% | 126,159 | -55,325 | -30.48% | 5,185,135 | Jun 30, 2024 |
As of Jun 30 2024, Ultragenyx Pharmaceutical's biggest institutional seller is RTW INVESTMENTS, LP. The company sold -3.83M shares of RARE, valued at $133.98M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NORGES BANK | 1.19% | 0.01% | 1,002,463 | 1,002,463 | 100.00% | 41,201,229 | Jun 30, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.50% | 0.82% | 425,000 | 425,000 | 100.00% | 17,467,500 | Jun 30, 2024 |
| CUTTER CAPITAL MANAGEMENT, LP | 0.43% | 4.53% | 365,000 | 365,000 | 100.00% | 15,001,500 | Jun 30, 2024 |
| D. E. SHAW & CO., INC. | 0.24% | 0.01% | 203,442 | 203,442 | 100.00% | 8,361,466 | Jun 30, 2024 |
| LMR PARTNERS LLP | 0.17% | 0.05% | 145,000 | 145,000 | 100.00% | 5,959,500 | Jun 30, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.12% | 0.53% | 100,000 | 100,000 | 100.00% | 4,110,000 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.12% | 0.55% | 100,000 | 100,000 | 100.00% | 4,110,000 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.11% | 0.01% | 92,824 | 92,824 | 100.00% | 3,816,586 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.08% | 0.02% | 70,000 | 70,000 | 100.00% | 2,877,000 | Jun 30, 2024 |
| ALTIUM CAPITAL MANAGEMENT LP | 0.08% | 1.17% | 70,000 | 70,000 | 100.00% | 2,877,000 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 0.07% | 0.01% | 58,800 | 58,800 | 100.00% | 2,416,680 | Jun 30, 2024 |
| WEISS ASSET MANAGEMENT LP | 0.06% | 0.08% | 50,000 | 50,000 | 100.00% | 2,055,000 | Jun 30, 2024 |
| TUDOR INVESTMENT CORP ET AL | 0.04% | 0.01% | 34,563 | 34,563 | 100.00% | 1,420,539 | Jun 30, 2024 |
| CAMPBELL & CO INVESTMENT ADVISER LLC | 0.04% | 0.12% | 33,868 | 33,868 | 100.00% | 1,391,975 | Jun 30, 2024 |
| CLEARLINE CAPITAL LP | 0.04% | 0.04% | 32,961 | 32,961 | 100.00% | 1,354,697 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | 0.03% | 0.02% | 27,289 | 27,289 | 100.00% | 1,121,578 | Jun 30, 2024 |
| S&CO INC | 0.02% | 0.06% | 20,255 | 20,255 | 100.00% | 832,000 | Jun 30, 2024 |
| OAK RIDGE INVESTMENTS LLC | 0.02% | 0.08% | 19,350 | 19,350 | 100.00% | 795,285 | Jun 30, 2024 |
| TWINBEECH CAPITAL LP | 0.02% | 0.01% | 17,813 | 17,813 | 100.00% | 732,114 | Jun 30, 2024 |
| CAPITAL FUND MANAGEMENT S.A. | 0.02% | 0.00% | 14,996 | 14,996 | 100.00% | 616,335 | Jun 30, 2024 |
| TOROSO INVESTMENTS, LLC | 0.02% | 0.01% | 13,676 | 13,676 | 100.00% | 562,083 | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | 0.01% | 0.00% | 10,250 | 10,250 | 100.00% | 421,275 | Jun 30, 2024 |
| PEARL RIVER CAPITAL, LLC | 0.01% | 0.05% | 7,671 | 7,671 | 100.00% | 315,278 | Jun 30, 2024 |
| SANDIA INVESTMENT MANAGEMENT LP | 0.01% | 0.38% | 7,500 | 7,500 | 100.00% | 308,250 | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | 0.01% | 0.00% | 6,137 | 6,137 | 100.00% | 259,228 | Jun 30, 2024 |
| NEWEDGE WEALTH, LLC | 0.01% | 0.01% | 5,945 | 5,945 | 100.00% | 244,340 | Jun 30, 2024 |
| VESTMARK ADVISORY SOLUTIONS, INC. | 0.01% | 0.01% | 5,945 | 5,945 | 100.00% | 244,340 | Jun 30, 2024 |
| HBK INVESTMENTS L P | 0.01% | 0.00% | 5,000 | 5,000 | 100.00% | 205,500 | Jun 30, 2024 |
| BELLEVUE GROUP AG | 0.00% | 0.00% | 4,000 | 4,000 | 100.00% | 164,400 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.00% | 0.00% | 1,736 | 1,736 | 100.00% | 71,350 | Jun 30, 2024 |
| NVERSES CAPITAL, LLC | 0.00% | 0.02% | 800 | 800 | 100.00% | 32,880 | Jun 30, 2024 |
| GROUPAMA ASSET MANAGMENT | 0.00% | 0.00% | 729 | 729 | 100.00% | 29,962 | Jun 30, 2024 |
| NBC SECURITIES, INC. | 0.00% | 0.00% | 159 | 159 | 100.00% | 6,000 | Jun 30, 2024 |
| PICTON MAHONEY ASSET MANAGEMENT | 0.00% | 0.00% | 147 | 147 | 100.00% | 6,000 | Jun 30, 2024 |
| BESSEMER GROUP INC | 0.00% | - | 140 | 140 | 100.00% | 6,000 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 100 | 100 | 100.00% | 4,110 | Jun 30, 2024 |
| VERSANT CAPITAL MANAGEMENT, INC | 0.00% | 0.00% | 78 | 78 | 100.00% | 3,206 | Jun 30, 2024 |
| JONES FINANCIAL COMPANIES LLLP | - | - | 38 | 38 | 100.00% | 1,562 | Jun 30, 2024 |
| CULLEN/FROST BANKERS, INC. | - | - | 36 | 36 | 100.00% | 1,480 | Jun 30, 2024 |
| LARSON FINANCIAL GROUP LLC | - | - | 17 | 17 | 100.00% | 699 | Jun 30, 2024 |
| INNEALTA CAPITAL, LLC | - | 0.00% | 15 | 15 | 100.00% | 617 | Jun 30, 2024 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | - | - | 3 | 3 | 100.00% | 123 | Jun 30, 2024 |
| MATHER GROUP, LLC. | - | - | 2 | 2 | 100.00% | 93 | Jun 30, 2024 |
Ultragenyx Pharmaceutical's largest new institutional shareholder by number of shares is NORGES BANK, purchased 1.00M shares, valued at $41.20M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| EVENTIDE ASSET MANAGEMENT, LLC | - | - | - | -359,000 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | - | - | - | -200,300 | -100.00% | - | Jun 30, 2024 |
| DEEP TRACK CAPITAL, LP | - | - | - | -167,784 | -100.00% | - | Jun 30, 2024 |
| NEUBERGER BERMAN GROUP LLC | - | - | - | -104,939 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -68,000 | -100.00% | - | Jun 30, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | - | - | - | -55,000 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -38,025 | -100.00% | - | Jun 30, 2024 |
| BARCLAYS PLC | - | - | - | -30,000 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -28,743 | -100.00% | - | Jun 30, 2024 |
| POINT72 HONG KONG LTD | - | - | - | -27,004 | -100.00% | - | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | - | - | - | -23,600 | -100.00% | - | Jun 30, 2024 |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | - | - | - | -23,005 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -22,631 | -100.00% | - | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| GHOST TREE CAPITAL, LLC | - | - | - | -20,000 | -100.00% | - | Jun 30, 2024 |
| EXOME ASSET MANAGEMENT LLC | - | - | - | -17,800 | -100.00% | - | Jun 30, 2024 |
| HSBC HOLDINGS PLC | - | - | - | -17,349 | -100.00% | - | Jun 30, 2024 |
| DYNAMIC TECHNOLOGY LAB PRIVATE LTD | - | - | - | -15,712 | -100.00% | - | Jun 30, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | - | - | - | -15,302 | -100.00% | - | Jun 30, 2024 |
| AXQ CAPITAL, LP | - | - | - | -14,600 | -100.00% | - | Jun 30, 2024 |
| QUEST PARTNERS LLC | - | - | - | -11,522 | -100.00% | - | Jun 30, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | - | - | - | -9,077 | -100.00% | - | Jun 30, 2024 |
| WINTON GROUP LTD | - | - | - | -8,755 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -7,869 | -100.00% | - | Jun 30, 2024 |
| GOTHAM ASSET MANAGEMENT, LLC | - | - | - | -7,478 | -100.00% | - | Jun 30, 2024 |
| WOLVERINE TRADING, LLC | - | - | - | -7,400 | -100.00% | - | Jun 30, 2024 |
| SAVANT CAPITAL, LLC | - | - | - | -7,245 | -100.00% | - | Jun 30, 2024 |
| TEZA CAPITAL MANAGEMENT LLC | - | - | - | -5,293 | -100.00% | - | Jun 30, 2024 |
| CORNERCAP INVESTMENT COUNSEL INC | - | - | - | -5,161 | -100.00% | - | Jun 30, 2024 |
| GTS SECURITIES LLC | - | - | - | -5,100 | -100.00% | - | Jun 30, 2024 |
| CAPSTONE INVESTMENT ADVISORS, LLC | - | - | - | -4,863 | -100.00% | - | Jun 30, 2024 |
| UTAH RETIREMENT SYSTEMS | - | - | - | -4,300 | -100.00% | - | Jun 30, 2024 |
| LAZARD ASSET MANAGEMENT LLC | - | - | - | -4,160 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | - | - | - | -3,587 | -100.00% | - | Jun 30, 2024 |
| QUARRY LP | - | - | - | -2,500 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -1,311 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -642 | -100.00% | - | Jun 30, 2024 |
| TRUVESTMENTS CAPITAL LLC | - | - | - | -158 | -100.00% | - | Jun 30, 2024 |
| TORNO CAPITAL, LLC | - | - | - | -100 | -100.00% | - | Jun 30, 2024 |
| SUNBELT SECURITIES, INC. | - | - | - | -86 | -100.00% | - | Jun 30, 2024 |
| FIRST PREMIER BANK | - | - | - | -53 | -100.00% | - | Jun 30, 2024 |
| ANFIELD CAPITAL MANAGEMENT, LLC | - | - | - | -40 | -100.00% | - | Jun 30, 2024 |
| RIGGS ASSET MANAGMENT CO. INC. | - | - | - | -22 | -100.00% | - | Jun 30, 2024 |
| CIBC PRIVATE WEALTH GROUP, LLC | - | - | - | -19 | -100.00% | - | Jun 30, 2024 |
Ultragenyx Pharmaceutical's largest sold out institutional shareholder by shares sold is EVENTIDE ASSET MANAGEMENT, LLC, sold -0.36M shares, valued at -, as of undefined.
Ultragenyx Pharmaceutical Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| SPARROW FUNDS | 2.40% | 8,570 | - | - | Feb 29, 2024 |
| Tema ETF Trust | 0.56% | 25,134 | 16,815 | 202.13% | Feb 29, 2024 |
| WANGER ADVISORS TRUST | 0.43% | 234,308 | - | - | Mar 31, 2024 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.39% | 1,288,587 | 8,052 | 0.63% | Mar 31, 2024 |
| AGF Investments Trust | 0.33% | -6,171 | - | - | Mar 31, 2024 |
| LORD ABBETT DEVELOPING GROWTH FUND, INC. | 0.30% | 274,635 | - | - | Jan 31, 2024 |
| LIBERTY ALL STAR GROWTH FUND INC. | 0.28% | 35,660 | 3,102 | 9.53% | Dec 31, 2023 |
| AB DISCOVERY GROWTH FUND, INC. | 0.23% | 342,361 | -9,473 | -2.69% | Jan 31, 2024 |
| HARTFORD HLS SERIES FUND II INC | 0.22% | 54,457 | 9,194 | 20.31% | Dec 31, 2023 |
| T. Rowe Price New Horizons Fund, Inc. | 0.21% | 1,050,818 | 45,370 | 4.51% | Mar 31, 2024 |
| ALGER FUNDS | 0.19% | 180,914 | -23,908 | -11.67% | Jan 31, 2024 |
| T. Rowe Price All-Cap Opportunities Fund, Inc. | 0.17% | 314,827 | - | - | Mar 31, 2024 |
| VANGUARD EXPLORER FUND | 0.16% | 2,001,943 | -228,530 | -10.25% | Jan 31, 2024 |
| TEKLA HEALTHCARE INVESTORS | 0.12% | 98,642 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.11% | 1,139,197 | - | - | Mar 31, 2024 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.11% | 364,857 | 16,592 | 4.76% | Mar 31, 2024 |
| Advantage Advisers Xanthus Fund, L.L.C. | 0.11% | 324,358 | - | - | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.11% | 2,124,721 | -291,779 | -12.07% | Jan 31, 2024 |
| T. Rowe Price Diversified Mid-Cap Growth Fund, Inc. | 0.11% | 36,900 | - | - | Mar 31, 2024 |
| BNY MELLON VARIABLE INVESTMENT FUND | 0.10% | 23,547 | - | - | Mar 31, 2024 |
| VANGUARD VALLEY FORGE FUNDS | 0.09% | 47,884 | - | - | Mar 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.09% | 17,522 | 7,664 | 77.74% | Mar 28, 2024 |
| FIRST TRUST EXCHANGE-TRADED ALPHADEX FUND | 0.09% | 351,752 | 343,089 | 3960.39% | Jan 31, 2024 |
| TEKLA LIFE SCIENCES INVESTORS | 0.09% | 42,475 | - | - | Mar 31, 2024 |
| NEW ECONOMY FUND | 0.09% | 398,772 | - | - | Feb 29, 2024 |
| ALGER FUNDS II | 0.09% | 19,626 | -5,772 | -22.73% | Jan 31, 2024 |
| Vanguard Montgomery Funds | 0.08% | 18,460 | - | - | Mar 31, 2024 |
| ACAP Strategic Fund | 0.07% | 1,092,706 | - | - | Mar 31, 2024 |
| AMERICAN FUNDS FUNDAMENTAL INVESTORS | 0.07% | 1,508,289 | - | - | Mar 31, 2024 |
| Nuveen NASDAQ 100 Dynamic Overwrite Fund | 0.07% | 8,154 | - | - | Mar 31, 2024 |
| HIGHLAND FUNDS II | 0.06% | 961 | - | - | Dec 31, 2023 |
| REYNOLDS FUNDS INC | 0.06% | 700 | - | - | Mar 31, 2024 |
| DELAWARE GROUP EQUITY FUNDS IV | 0.06% | 70,178 | -723 | -1.02% | Mar 28, 2024 |
| BlackRock Health Sciences Trust | 0.06% | 14,268 | 54 | 0.38% | Mar 31, 2024 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 0.05% | 178,930 | - | - | Mar 31, 2024 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 0.05% | 733,449 | - | - | Mar 31, 2024 |
| BlackRock Health Sciences Trust II | 0.04% | 118,142 | 378 | 0.32% | Mar 31, 2024 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 0.04% | 331,553 | - | - | Mar 31, 2024 |
| NEW PERSPECTIVE FUND | 0.04% | 1,228,978 | - | - | Mar 31, 2024 |
| T. Rowe Price Equity Series, Inc. | 0.04% | 61,717 | 1,000 | 1.65% | Mar 31, 2024 |
| T. Rowe Price Tax-Efficient Funds, Inc. | 0.04% | 3,500 | - | - | Feb 29, 2024 |
| Fidelity Commonwealth Trust II | 0.03% | 207,284 | - | - | Aug 31, 2023 |
| TOUCHSTONE FUNDS GROUP TRUST | 0.03% | 790,346 | -33,912 | -4.11% | Mar 31, 2024 |
| Voya VARIABLE PRODUCTS TRUST | 0.03% | 10,593 | - | - | Mar 31, 2024 |
| VANGUARD HORIZON FUNDS | 0.03% | 694,750 | -184,468 | -20.98% | Mar 31, 2024 |
| Humankind Benefit Corp | 0.03% | 587 | -88 | -13.04% | Dec 31, 2023 |
| VANGUARD SPECIALIZED FUNDS | 0.02% | 1,245,879 | - | - | Jan 31, 2024 |
| LEGG MASON PARTNERS VARIABLE EQUITY TRUST | 0.02% | 84,654 | - | - | Dec 29, 2023 |
| GROWTH FUND OF AMERICA | 0.02% | 505,857 | - | - | Feb 29, 2024 |
| Collaborative Investment Series Trust | 0.02% | 2,758 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.02% | 10,355 | - | - | Mar 31, 2024 |
| RMB INVESTORS TRUST | 0.02% | 9,079 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY GROWTH FUNDS, INC. | 0.02% | 2,622 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.02% | 6,803,477 | -1,317,359 | -16.22% | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 96,407 | - | - | Mar 31, 2024 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 906,930 | -132,500 | -12.75% | Feb 29, 2024 |
| AB CAP FUND, INC. | 0.01% | 384,500 | -41,593 | -9.76% | Jan 31, 2024 |
| DRIEHAUS MUTUAL FUNDS | 0.01% | 81,939 | 9,883 | 13.72% | Mar 28, 2024 |
| T. Rowe Price Equity Funds, Inc. | 0.01% | 94,431 | - | - | Mar 31, 2024 |
| LEGG MASON PARTNERS INVESTMENT TRUST | 0.01% | 436,003 | - | - | Feb 29, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,912 | - | - | Mar 31, 2024 |
| Bernstein Fund Inc | 0.01% | 71,594 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENT TRUST | 0.01% | 24,052 | - | - | Mar 31, 2024 |
| FIDELITY COMMONWEALTH TRUST | 0.01% | 24,038 | 372 | 1.57% | Feb 29, 2024 |
| FRANKLIN STRATEGIC SERIES | 0.01% | 63,321 | 2,625 | 4.32% | Jan 31, 2024 |
| Harbor ETF Trust | 0.01% | 35,086 | 3,022 | 9.42% | Jan 31, 2024 |
| Calvert Responsible Index Series, Inc. | 0.01% | 12,103 | - | - | Mar 31, 2024 |
| HARTFORD SERIES FUND INC | 0.01% | 311,665 | -36,951 | -10.60% | Mar 31, 2024 |
| JNL VARIABLE FUND LLC | 0.01% | 39,325 | -2,002 | -4.84% | Mar 31, 2020 |
| MFS SERIES TRUST I | 0.01% | 135,693 | 135,693 | - | Feb 29, 2024 |
| EntrepreneurShares Series Trust | 0.01% | 1,572 | - | - | Dec 31, 2023 |
| RYDEX SERIES FUNDS | 0.01% | 23,809 | 1,387 | 6.19% | Dec 31, 2023 |
| NEUBERGER BERMAN EQUITY FUNDS | 0.01% | 52,367 | -36,808 | -41.28% | Feb 29, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.01% | 23,415 | -6,585 | -21.95% | Mar 31, 2024 |
| COLUMBIA ACORN TRUST | 0.01% | 16,200 | - | - | Mar 31, 2024 |
| ETFis Series Trust I | 0.00% | 7,105 | 1,033 | 17.01% | Jan 31, 2024 |
| Voya EQUITY TRUST | 0.00% | 6,199 | - | - | Feb 29, 2024 |
| SMALLCAP WORLD FUND INC | 0.00% | 295,412 | - | - | Mar 31, 2024 |
| SARATOGA ADVANTAGE TRUST | 0.00% | 233 | - | - | Feb 29, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 780,148 | 52,591 | 7.23% | Feb 29, 2024 |
| ALPS ETF Trust | 0.00% | 46,545 | - | - | Feb 29, 2024 |
| FIDELITY MT VERNON STREET TRUST | 0.00% | 95,887 | - | - | Feb 29, 2024 |
| SunAmerica Specialty Series | 0.00% | 1,701 | -138 | -7.50% | Apr 30, 2021 |
| Forethought Variable Insurance Trust | 0.00% | 13,642 | -6,523 | -32.35% | Mar 28, 2024 |
| Federated Hermes MDT Series | 0.00% | 7,231 | - | - | Jan 31, 2024 |
| AMG Funds IV | 0.00% | 8,759 | -262 | -2.90% | Jan 31, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 3,347 | 867 | 34.96% | Dec 31, 2023 |
| HIGHLAND GLOBAL ALLOCATION FUND | 0.00% | 2,800 | - | - | Dec 31, 2023 |
| FINANCIAL INVESTORS TRUST | 0.00% | 203,776 | - | - | Jan 31, 2024 |
| AMERICAN CENTURY QUANTITATIVE EQUITY FUNDS, INC. | 0.00% | 5,723 | - | - | Mar 31, 2024 |
| DELAWARE GROUP EQUITY FUNDS V | 0.00% | 139,443 | - | - | Feb 29, 2024 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 254,305 | -21,316 | -7.73% | Mar 31, 2024 |
| John Hancock Exchange-Traded Fund Trust | 0.00% | 13,515 | - | - | Jan 31, 2024 |
| Global X Funds | 0.00% | 97,827 | - | - | Jan 31, 2024 |
| Nushares ETF Trust | 0.00% | 15,814 | -2,618 | -14.20% | Jan 31, 2024 |
| FIDELITY CONTRAFUND | 0.00% | 140,100 | - | - | Mar 31, 2024 |
| MUTUAL OF AMERICA INSTITUTIONAL FUNDS INC | 0.00% | 1,157 | 543 | 88.44% | Sep 30, 2020 |
| FIDELITY COVINGTON TRUST | 0.00% | 37,575 | 156 | 0.42% | Jan 31, 2024 |
| Goldman Sachs ETF Trust II | 0.00% | 2,134 | - | - | Feb 29, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 5,245 | - | - | Mar 31, 2024 |
Ultragenyx Pharmaceutical's largest mutual fund holder by % of total assets is "SPARROW FUNDS", owning 8.57K shares, compromising 2.40% of its total assets.
Ultragenyx Pharmaceutical Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 103 | -63.08% |
| 31 Mar, 24 | 279 | 11.16% |
| 31 Dec, 23 | 251 | 6.81% |
| 30 Sep, 23 | 235 | -6.75% |
| 30 Jun, 23 | 252 | 6.33% |
| 31 Mar, 23 | 237 | -0.42% |
| 31 Dec, 22 | 238 | 0.42% |
| 30 Sep, 22 | 237 | 5.80% |
| 30 Jun, 22 | 224 | -9.31% |
| 31 Mar, 22 | 247 | 5.11% |
| 31 Dec, 21 | 235 | 4.44% |
| 30 Sep, 21 | 225 | -8.16% |
| 30 Jun, 21 | 245 | -8.92% |
| 31 Mar, 21 | 269 | - |
| 31 Dec, 20 | 269 | 27.49% |
| 30 Sep, 20 | 211 | 3.94% |
| 30 Jun, 20 | 203 | 12.78% |
| 31 Mar, 20 | 180 | - |
| 31 Dec, 19 | 180 | 2.27% |
| 30 Sep, 19 | 176 | 1.15% |
| 30 Jun, 19 | 174 | -4.40% |
| 31 Mar, 19 | 182 | 10.30% |
| 31 Dec, 18 | 165 | -8.84% |
| 30 Sep, 18 | 181 | 11.04% |
| 30 Jun, 18 | 163 | -2.98% |
| 31 Mar, 18 | 168 | -1.18% |
| 31 Dec, 17 | 170 | 5.59% |
| 30 Sep, 17 | 161 | -5.29% |
| 30 Jun, 17 | 170 | -2.30% |
| 31 Mar, 17 | 174 | -5.43% |
| 31 Dec, 16 | 184 | -1.60% |
| 30 Sep, 16 | 187 | 12.65% |
| 30 Jun, 16 | 166 | -3.49% |
| 31 Mar, 16 | 172 | -4.44% |
| 31 Dec, 15 | 180 | 3.45% |
| 30 Sep, 15 | 174 | 8.75% |
| 30 Jun, 15 | 160 | 22.14% |
| 31 Mar, 15 | 131 | 25.96% |
| 31 Dec, 14 | 104 | 0.97% |
| 30 Sep, 14 | 103 | 22.62% |
| 30 Jun, 14 | 84 | 9.09% |
| 31 Mar, 14 | 77 | - |
As of 30 Jun 24, 103 institutions are holding Ultragenyx Pharmaceutical's shares, representing a decrease of -63.08% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 10,755,826 | -86.40% |
| 31 Mar, 24 | 79,067,043 | -1.61% |
| 31 Dec, 23 | 80,357,498 | 14.79% |
| 30 Sep, 23 | 70,004,468 | 1.62% |
| 30 Jun, 23 | 68,890,236 | 0.27% |
| 31 Mar, 23 | 68,707,512 | 0.97% |
| 31 Dec, 22 | 68,047,481 | 0.31% |
| 30 Sep, 22 | 67,836,176 | 0.46% |
| 30 Jun, 22 | 67,528,208 | 0.39% |
| 31 Mar, 22 | 67,267,848 | -0.66% |
| 31 Dec, 21 | 67,712,517 | 1.64% |
| 30 Sep, 21 | 66,617,492 | 1.82% |
| 30 Jun, 21 | 65,424,487 | -3.57% |
| 31 Mar, 21 | 67,847,970 | 0.31% |
| 31 Dec, 20 | 67,641,568 | 7.24% |
| 30 Sep, 20 | 63,076,153 | -0.06% |
| 30 Jun, 20 | 63,113,266 | 5.01% |
| 31 Mar, 20 | 60,101,329 | 3.29% |
| 31 Dec, 19 | 58,185,343 | -0.80% |
| 30 Sep, 19 | 58,651,732 | -0.29% |
| 30 Jun, 19 | 58,823,805 | 0.94% |
| 31 Mar, 19 | 58,275,003 | 15.28% |
| 31 Dec, 18 | 50,549,665 | 1.59% |
| 30 Sep, 18 | 49,757,454 | 1.94% |
| 30 Jun, 18 | 48,810,229 | -0.27% |
| 31 Mar, 18 | 48,942,899 | 13.17% |
| 31 Dec, 17 | 43,247,481 | 6.53% |
| 30 Sep, 17 | 40,596,664 | -1.73% |
| 30 Jun, 17 | 41,312,001 | 1.43% |
| 31 Mar, 17 | 40,729,523 | -2.16% |
| 31 Dec, 16 | 41,627,583 | 5.31% |
| 30 Sep, 16 | 39,527,731 | 6.88% |
| 30 Jun, 16 | 36,983,814 | -1.07% |
| 31 Mar, 16 | 37,383,857 | 5.08% |
| 31 Dec, 15 | 35,576,523 | 0.59% |
| 30 Sep, 15 | 35,369,430 | 8.75% |
| 30 Jun, 15 | 32,522,715 | 2.83% |
| 31 Mar, 15 | 31,628,694 | 13.00% |
| 31 Dec, 14 | 27,989,671 | 5.64% |
| 30 Sep, 14 | 26,496,472 | 31.28% |
| 30 Jun, 14 | 20,183,138 | 6.57% |
| 31 Mar, 14 | 18,938,424 | - |
Ultragenyx Pharmaceutical (RARE) has 10.76M shares outstanding as of 30 Jun 24, down -86.40% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 12.76% | 0.13% |
| 31 Mar, 24 | 97.47% | 0.78% |
| 31 Dec, 23 | 112.13% | 1.15% |
| 30 Sep, 23 | 98.74% | 1.03% |
| 30 Jun, 23 | 97.90% | 1.03% |
| 31 Mar, 23 | 97.64% | 1.04% |
| 31 Dec, 22 | 97.00% | 1.03% |
| 30 Sep, 22 | 96.83% | 1.04% |
| 30 Jun, 22 | 96.57% | 1.03% |
| 31 Mar, 22 | 96.77% | 0.99% |
| 31 Dec, 21 | 98.75% | 1.03% |
| 30 Sep, 21 | 98.15% | 1.05% |
| 30 Jun, 21 | 96.77% | 0.95% |
| 31 Mar, 21 | 101.11% | 0.92% |
| 31 Dec, 20 | 104.61% | 0.97% |
| 30 Sep, 20 | 103.94% | 0.94% |
| 30 Jun, 20 | 105.20% | 0.98% |
| 31 Mar, 20 | 103.63% | 0.98% |
| 31 Dec, 19 | 102.84% | 1.00% |
| 30 Sep, 19 | 101.64% | 0.97% |
| 30 Jun, 19 | 102.27% | 0.85% |
| 31 Mar, 19 | 109.52% | 1.06% |
| 31 Dec, 18 | 101.56% | 1.04% |
| 30 Sep, 18 | 98.88% | 1.03% |
| 30 Jun, 18 | 97.97% | 0.95% |
| 31 Mar, 18 | 101.56% | 1.01% |
| 31 Dec, 17 | 100.25% | 1.10% |
| 30 Sep, 17 | 95.59% | 1.00% |
| 30 Jun, 17 | 97.56% | 1.03% |
| 31 Mar, 17 | 97.34% | 0.88% |
| 31 Dec, 16 | 105.15% | 1.05% |
| 30 Sep, 16 | 99.94% | 1.11% |
| 30 Jun, 16 | 94.76% | 1.03% |
| 31 Mar, 16 | 95.93% | 1.03% |
| 31 Dec, 15 | 96.72% | 1.13% |
| 30 Sep, 15 | 92.42% | 1.13% |
| 30 Jun, 15 | 90.50% | 1.05% |
| 31 Mar, 15 | 93.00% | 0.98% |
| 31 Dec, 14 | 97.34% | 1.39% |
| 30 Sep, 14 | 83.77% | 1.86% |
| 30 Jun, 14 | 67.15% | 0.87% |
| 31 Mar, 14 | 87.75% | - |
As of 30 Jun 24, Ultragenyx Pharmaceutical is held by 12.76% institutional shareholders, representing a 0.13% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 58 | -61.59% |
| 31 Mar, 24 | 151 | 8.63% |
| 31 Dec, 23 | 139 | 19.83% |
| 30 Sep, 23 | 116 | -13.43% |
| 30 Jun, 23 | 134 | 14.53% |
| 31 Mar, 23 | 117 | -18.18% |
| 31 Dec, 22 | 143 | 2.14% |
| 30 Sep, 22 | 140 | 17.65% |
| 30 Jun, 22 | 119 | -7.03% |
| 31 Mar, 22 | 128 | 0.79% |
| 31 Dec, 21 | 127 | 14.41% |
| 30 Sep, 21 | 111 | -5.93% |
| 30 Jun, 21 | 118 | -9.23% |
| 31 Mar, 21 | 130 | -19.75% |
| 31 Dec, 20 | 162 | 35.00% |
| 30 Sep, 20 | 120 | 16.50% |
| 30 Jun, 20 | 103 | 7.29% |
| 31 Mar, 20 | 96 | -3.03% |
| 31 Dec, 19 | 99 | -1.00% |
| 30 Sep, 19 | 100 | 3.09% |
| 30 Jun, 19 | 97 | -20.49% |
| 31 Mar, 19 | 122 | 43.53% |
| 31 Dec, 18 | 85 | 2.41% |
| 30 Sep, 18 | 83 | 7.79% |
| 30 Jun, 18 | 77 | -20.62% |
| 31 Mar, 18 | 97 | 14.12% |
| 31 Dec, 17 | 85 | 14.86% |
| 30 Sep, 17 | 74 | -20.43% |
| 30 Jun, 17 | 93 | 5.68% |
| 31 Mar, 17 | 88 | - |
| 31 Dec, 16 | 88 | -7.37% |
| 30 Sep, 16 | 95 | 17.28% |
| 30 Jun, 16 | 81 | -14.74% |
| 31 Mar, 16 | 95 | -4.04% |
| 31 Dec, 15 | 99 | -18.18% |
| 30 Sep, 15 | 121 | 26.04% |
| 30 Jun, 15 | 96 | 5.49% |
| 31 Mar, 15 | 91 | 49.18% |
| 31 Dec, 14 | 61 | -15.28% |
| 30 Sep, 14 | 72 | 56.52% |
| 30 Jun, 14 | 46 | -40.26% |
| 31 Mar, 14 | 77 | - |
58 institutional shareholders have increased their position in RARE stock as of 30 Jun 24 compared to 151 in the previous quarter (a -61.59% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 26 | -67.09% |
| 31 Mar, 24 | 79 | 3.95% |
| 31 Dec, 23 | 76 | 1.33% |
| 30 Sep, 23 | 75 | -5.06% |
| 30 Jun, 23 | 79 | -2.47% |
| 31 Mar, 23 | 81 | 32.79% |
| 31 Dec, 22 | 61 | 1.67% |
| 30 Sep, 22 | 60 | -14.29% |
| 30 Jun, 22 | 70 | -2.78% |
| 31 Mar, 22 | 72 | 4.35% |
| 31 Dec, 21 | 69 | -10.39% |
| 30 Sep, 21 | 77 | -12.50% |
| 30 Jun, 21 | 88 | -11.11% |
| 31 Mar, 21 | 99 | 41.43% |
| 31 Dec, 20 | 70 | 9.38% |
| 30 Sep, 20 | 64 | 1.59% |
| 30 Jun, 20 | 63 | 34.04% |
| 31 Mar, 20 | 47 | -4.08% |
| 31 Dec, 19 | 49 | 6.52% |
| 30 Sep, 19 | 46 | 6.98% |
| 30 Jun, 19 | 43 | 48.28% |
| 31 Mar, 19 | 29 | -43.14% |
| 31 Dec, 18 | 51 | -12.07% |
| 30 Sep, 18 | 58 | 5.45% |
| 30 Jun, 18 | 55 | 48.65% |
| 31 Mar, 18 | 37 | -22.92% |
| 31 Dec, 17 | 48 | 4.35% |
| 30 Sep, 17 | 46 | 4.55% |
| 30 Jun, 17 | 44 | -27.87% |
| 31 Mar, 17 | 61 | - |
| 31 Dec, 16 | 61 | 7.02% |
| 30 Sep, 16 | 57 | -6.56% |
| 30 Jun, 16 | 61 | 15.09% |
| 31 Mar, 16 | 53 | 3.92% |
| 31 Dec, 15 | 51 | 64.52% |
| 30 Sep, 15 | 31 | -22.50% |
| 30 Jun, 15 | 40 | 60.00% |
| 31 Mar, 15 | 25 | 4.17% |
| 31 Dec, 14 | 24 | 20.00% |
| 30 Sep, 14 | 20 | -23.08% |
| 30 Jun, 14 | 26 | - |
| 31 Mar, 14 | - | - |
26 institutional shareholders have reduced their position in RARE stock as of 30 Jun 24 compared to 79 in the previous quarter (a -67.09% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 103 | -63.08% | 10,755,826 | -86.40% | 12.76% | 0.13% | 58 | -61.59% | 26 | -67.09% |
| 31 Mar, 24 | 279 | 11.16% | 79,067,043 | -1.61% | 97.47% | 0.78% | 151 | 8.63% | 79 | 3.95% |
| 31 Dec, 23 | 251 | 6.81% | 80,357,498 | 14.79% | 112.13% | 1.15% | 139 | 19.83% | 76 | 1.33% |
| 30 Sep, 23 | 235 | -6.75% | 70,004,468 | 1.62% | 98.74% | 1.03% | 116 | -13.43% | 75 | -5.06% |
| 30 Jun, 23 | 252 | 6.33% | 68,890,236 | 0.27% | 97.90% | 1.03% | 134 | 14.53% | 79 | -2.47% |
| 31 Mar, 23 | 237 | -0.42% | 68,707,512 | 0.97% | 97.64% | 1.04% | 117 | -18.18% | 81 | 32.79% |
| 31 Dec, 22 | 238 | 0.42% | 68,047,481 | 0.31% | 97.00% | 1.03% | 143 | 2.14% | 61 | 1.67% |
| 30 Sep, 22 | 237 | 5.80% | 67,836,176 | 0.46% | 96.83% | 1.04% | 140 | 17.65% | 60 | -14.29% |
| 30 Jun, 22 | 224 | -9.31% | 67,528,208 | 0.39% | 96.57% | 1.03% | 119 | -7.03% | 70 | -2.78% |
| 31 Mar, 22 | 247 | 5.11% | 67,267,848 | -0.66% | 96.77% | 0.99% | 128 | 0.79% | 72 | 4.35% |
| 31 Dec, 21 | 235 | 4.44% | 67,712,517 | 1.64% | 98.75% | 1.03% | 127 | 14.41% | 69 | -10.39% |
| 30 Sep, 21 | 225 | -8.16% | 66,617,492 | 1.82% | 98.15% | 1.05% | 111 | -5.93% | 77 | -12.50% |
| 30 Jun, 21 | 245 | -8.92% | 65,424,487 | -3.57% | 96.77% | 0.95% | 118 | -9.23% | 88 | -11.11% |
| 31 Mar, 21 | 269 | - | 67,847,970 | 0.31% | 101.11% | 0.92% | 130 | -19.75% | 99 | 41.43% |
| 31 Dec, 20 | 269 | 27.49% | 67,641,568 | 7.24% | 104.61% | 0.97% | 162 | 35.00% | 70 | 9.38% |
| 30 Sep, 20 | 211 | 3.94% | 63,076,153 | -0.06% | 103.94% | 0.94% | 120 | 16.50% | 64 | 1.59% |
| 30 Jun, 20 | 203 | 12.78% | 63,113,266 | 5.01% | 105.20% | 0.98% | 103 | 7.29% | 63 | 34.04% |
| 31 Mar, 20 | 180 | - | 60,101,329 | 3.29% | 103.63% | 0.98% | 96 | -3.03% | 47 | -4.08% |
| 31 Dec, 19 | 180 | 2.27% | 58,185,343 | -0.80% | 102.84% | 1.00% | 99 | -1.00% | 49 | 6.52% |
| 30 Sep, 19 | 176 | 1.15% | 58,651,732 | -0.29% | 101.64% | 0.97% | 100 | 3.09% | 46 | 6.98% |
| 30 Jun, 19 | 174 | -4.40% | 58,823,805 | 0.94% | 102.27% | 0.85% | 97 | -20.49% | 43 | 48.28% |
| 31 Mar, 19 | 182 | 10.30% | 58,275,003 | 15.28% | 109.52% | 1.06% | 122 | 43.53% | 29 | -43.14% |
| 31 Dec, 18 | 165 | -8.84% | 50,549,665 | 1.59% | 101.56% | 1.04% | 85 | 2.41% | 51 | -12.07% |
| 30 Sep, 18 | 181 | 11.04% | 49,757,454 | 1.94% | 98.88% | 1.03% | 83 | 7.79% | 58 | 5.45% |
| 30 Jun, 18 | 163 | -2.98% | 48,810,229 | -0.27% | 97.97% | 0.95% | 77 | -20.62% | 55 | 48.65% |
| 31 Mar, 18 | 168 | -1.18% | 48,942,899 | 13.17% | 101.56% | 1.01% | 97 | 14.12% | 37 | -22.92% |
| 31 Dec, 17 | 170 | 5.59% | 43,247,481 | 6.53% | 100.25% | 1.10% | 85 | 14.86% | 48 | 4.35% |
| 30 Sep, 17 | 161 | -5.29% | 40,596,664 | -1.73% | 95.59% | 1.00% | 74 | -20.43% | 46 | 4.55% |
| 30 Jun, 17 | 170 | -2.30% | 41,312,001 | 1.43% | 97.56% | 1.03% | 93 | 5.68% | 44 | -27.87% |
| 31 Mar, 17 | 174 | -5.43% | 40,729,523 | -2.16% | 97.34% | 0.88% | 88 | - | 61 | - |
| 31 Dec, 16 | 184 | -1.60% | 41,627,583 | 5.31% | 105.15% | 1.05% | 88 | -7.37% | 61 | 7.02% |
| 30 Sep, 16 | 187 | 12.65% | 39,527,731 | 6.88% | 99.94% | 1.11% | 95 | 17.28% | 57 | -6.56% |
| 30 Jun, 16 | 166 | -3.49% | 36,983,814 | -1.07% | 94.76% | 1.03% | 81 | -14.74% | 61 | 15.09% |
| 31 Mar, 16 | 172 | -4.44% | 37,383,857 | 5.08% | 95.93% | 1.03% | 95 | -4.04% | 53 | 3.92% |
| 31 Dec, 15 | 180 | 3.45% | 35,576,523 | 0.59% | 96.72% | 1.13% | 99 | -18.18% | 51 | 64.52% |
| 30 Sep, 15 | 174 | 8.75% | 35,369,430 | 8.75% | 92.42% | 1.13% | 121 | 26.04% | 31 | -22.50% |
| 30 Jun, 15 | 160 | 22.14% | 32,522,715 | 2.83% | 90.50% | 1.05% | 96 | 5.49% | 40 | 60.00% |
| 31 Mar, 15 | 131 | 25.96% | 31,628,694 | 13.00% | 93.00% | 0.98% | 91 | 49.18% | 25 | 4.17% |
| 31 Dec, 14 | 104 | 0.97% | 27,989,671 | 5.64% | 97.34% | 1.39% | 61 | -15.28% | 24 | 20.00% |
| 30 Sep, 14 | 103 | 22.62% | 26,496,472 | 31.28% | 83.77% | 1.86% | 72 | 56.52% | 20 | -23.08% |
| 30 Jun, 14 | 84 | 9.09% | 20,183,138 | 6.57% | 67.15% | 0.87% | 46 | -40.26% | 26 | - |
| 31 Mar, 14 | 77 | - | 18,938,424 | - | 87.75% | - | 77 | - | - | - |
Ultragenyx Pharmaceutical Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Ultragenyx Pharmaceutical's stock was made by KAKKIS EMIL D on Aug 07 2024, selling 20,000 shares at $50.17 per share (valued at $1.00M).
Ultragenyx Pharmaceutical Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 2 | - |
| Q2 2024 | 14 | 5 | 280.00% |
| Q1 2024 | 27 | 17 | 158.82% |
| Q4 2023 | 5 | 5 | 100.00% |
| Q3 2023 | 3 | 6 | 50.00% |
| Q2 2023 | 17 | 16 | 106.25% |
| Q1 2023 | 21 | 13 | 161.54% |
| Q4 2022 | - | 4 | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 25 | 2 | 1250.00% |
| Q1 2022 | 24 | 15 | 160.00% |
| Q4 2021 | - | 11 | - |
| Q3 2021 | 3 | 9 | 33.33% |
| Q2 2021 | 18 | 16 | 112.50% |
| Q1 2021 | 28 | 20 | 140.00% |
| Q4 2020 | 6 | 19 | 31.58% |
| Q3 2020 | 13 | 29 | 44.83% |
| Q2 2020 | 23 | 47 | 48.94% |
| Q1 2020 | 29 | 11 | 263.64% |
| Q4 2019 | 9 | 1 | 900.00% |
0 total buy trades, and 2 total sell trades (buy/sell ratio of 0.00%) were made by Ultragenyx Pharmaceutical's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | 2 | - |
| Q2 2024 | - | 4 | - |
| Q1 2024 | - | 11 | - |
| Q4 2023 | - | 3 | - |
| Q3 2023 | - | 5 | - |
| Q2 2023 | - | 5 | - |
| Q1 2023 | - | 8 | - |
| Q4 2022 | - | 4 | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | 2 | - |
| Q1 2022 | - | 12 | - |
| Q4 2021 | - | 9 | - |
| Q3 2021 | - | 4 | - |
| Q2 2021 | - | 14 | - |
| Q1 2021 | - | 15 | - |
| Q4 2020 | - | 14 | - |
| Q3 2020 | - | 15 | - |
| Q2 2020 | - | 15 | - |
| Q1 2020 | - | 1 | - |
| Q4 2019 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Ultragenyx Pharmaceutical's stocks.
Ultragenyx Pharmaceutical Peer Ownership
| Ticker | Company |
|---|---|
| INCY | Incyte Corporation |
| XFOR | X4 Pharmaceuticals, Inc. |
| ARVN | Arvinas, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| ALNY | Alnylam Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| INZY | Inozyme Pharma, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| UTHR | United Therapeutics Corporation |
| KURA | Kura Oncology, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
RARE Ownership FAQ
Who Owns Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical is owned by institutional shareholders (12.76%), insiders (3.66%), and public (83.58%). The largest institutional shareholder of Ultragenyx Pharmaceutical is VANGUARD GROUP INC (11.60% of total shares) and the top mutual fund owner is SPARROW FUNDS (2.40% of total shares).
Who are the major institutional shareholders of Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's major institutional shareholders are VANGUARD GROUP INC, BLACKROCK INC., SANDS CAPITAL MANAGEMENT, LLC, WELLINGTON MANAGEMENT GROUP LLP, and RTW INVESTMENTS, LP. The top five shareholders own together 33.88% of the company's share outstanding.
How many Ultragenyx Pharmaceutical shareholders are there?
As of Jun 2024, there are 103 institutional shareholders of Ultragenyx Pharmaceutical.
What percentage of Ultragenyx Pharmaceutical is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC owns 9.78M shares of Ultragenyx Pharmaceutical, representing 11.60% of the company's total shares outstanding, valued at $401.98M (as of Jun 2024).
What percentage of Ultragenyx Pharmaceutical is owned by BLACKROCK INC?
As of Jun 2024, BLACKROCK INC holds 5.6M shares of Ultragenyx Pharmaceutical (RARE), compromising 6.65% of the company, valued at $230.3M.
What percentage of Ultragenyx Pharmaceutical is owned by SANDS CAPITAL MANAGEMENT, LLC?
SANDS CAPITAL MANAGEMENT, LLC is the third largest holder of Ultragenyx Pharmaceutical. The company owns 5.35M of the company's shares outstanding (worth $220.08M).